Skip to content
Canadian Pharmacy Regulatory Authorities:
AB
BC
MB
NB
NL
NS
NT
NU
ON
PE
QC
SK
YT
All
Search for:
Search
Search
National Drug Schedules Program
Menu Toggle
NDS Database
About the NDS Program
Menu Toggle
Drug Scheduling in Canada
What Are the NDS?
NDS Policies
NDS Implementation Across Canada
Subscribe to NDS Updates
NDS Submissions
NDS Process
Menu Toggle
Summary of the NDS Process
Participation in NDS Reviews
NDS Advisory Committee
Menu Toggle
National Drug Scheduling Advisory Committee (NDSAC)
NDSAC Meetings
Resources
Menu Toggle
Publications
NAPRA Diagnostic Tool and Learning Modules (DTLM)
National Statistics
Pharmacy Regulatory Authorities
Online Pharmacies
International
News
Main Menu
National Drug Schedules Program
Menu Toggle
NDS Database
About the NDS Program
Menu Toggle
Drug Scheduling in Canada
What Are the NDS?
NDS Policies
NDS Implementation Across Canada
Subscribe to NDS Updates
NDS Submissions
NDS Process
Menu Toggle
Summary of the NDS Process
Participation in NDS Reviews
NDS Advisory Committee
Menu Toggle
National Drug Scheduling Advisory Committee (NDSAC)
NDSAC Meetings
Resources
Menu Toggle
Publications
NAPRA Diagnostic Tool and Learning Modules (DTLM)
National Statistics
Pharmacy Regulatory Authorities
Online Pharmacies
International
News
Login
NAPRA Groups
Inebilizumab
Inebilizumab
Approval Date:
February 28, 2024
Schedule:
I
Footnote:
PDL
